CHICAGO -- Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions. With numerous ...

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...

Rybrevant (amivantamab) has been cleared in combination with chemotherapy for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations who have previously ...

The combination of amivantamab and lazertinib shows lower EGFR and MET resistance, offering an advantage over osimertinib alone. Personalized treatment strategies are essential, considering resistance ...

First-line treatment with amivantamab–lazertinib may improve clinical outcomes. New research findings are summarized in a short video.

Alert FDA Expands Indication for Amivantamab in Lung Cancer Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...